Literature DB >> 20224458

I-123 MIBG cardiac uptake measurements: limitations of collimator choice and scatter correction in the clinical context.

Alison M Fletcher1, Duncan W Motherwell, Alexander D Small, Graham M McCurrach, Nicholas E R Goodfield, Mark C Petrie, William Martin, Stuart M Cobbe.   

Abstract

OBJECTIVE: Low uptake of metaiodobenzylguanidine (MIBG) in patients with heart failure generally indicates poor prognosis. Our objective was to determine the best method for calculating I-123 MIBG uptake. MIBG uptake as a percentage of the injected dose is presented as an alternative method for serial assessment.
METHODS: Patients with chronic heart failure were imaged with I-123 MIBG with both a medium-energy (ME) collimator and a low-energy high-sensitivity (LEHS) collimator. Scatter correction was used to correct the LEHS images. Heart-to-mediastinal (H/M) ratio and the percentage of myocardial uptake of MIBG were obtained.
RESULTS: Mean H/M ratios for the ME images, LEHS images and scatter-corrected LEHS images were 2.45+/-0.61, 2.22+/-0.47 and 2.51+/-0.62, respectively. Mean H/M ratio was significantly different among all the three sets (P<0.001) of images. The average difference in H/M ratios between the ME images and LEHS images was lower when scatter correction was applied (4.95% vs. 9.79%). The error in calculating the myocardial uptake as a percentage of the injected dose was significantly lower than the error in calculating H/M ratio (0.2 vs.10.2% LEHS; 0.3 vs.16.0% ME; 0.2 vs.11.8% LEHS scatter corrected).
CONCLUSION: For quantitative assessment of H/M ratio in I-123 MIBG imaging a LEHS collimator can be used in place of a ME collimator to achieve better counting statistics, but scatter correction must be used. The calculation of the myocardial uptake as a percentage of the injected dose has potential as an alternative method of measurement, particularly for serial assessment. 2010 Wolters Kluwer Health / Lippincott Williams & Wilkins.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20224458     DOI: 10.1097/MNM.0b013e3283375639

Source DB:  PubMed          Journal:  Nucl Med Commun        ISSN: 0143-3636            Impact factor:   1.690


  4 in total

1.  Quantification of I-123-meta-iodobenzylguanidine heart-to-mediastinum ratios: not so simple after all.

Authors:  Piotr J Slomka; Puja K Mehta; Guido Germano; Daniel S Berman
Journal:  J Nucl Cardiol       Date:  2014-07-09       Impact factor: 5.952

Review 2.  Variation of heart-to-mediastinal ratio in (123)I-mIBG cardiac sympathetic imaging: its affecting factors and potential corrections.

Authors:  Wengen Chen; Qi Cao; Vasken Dilsizian
Journal:  Curr Cardiol Rep       Date:  2011-04       Impact factor: 2.931

3.  Impact of a predefined mediastinal ROI on inter-observer variability of planar ¹²³I-MIBG heart-to-mediastinum ratio.

Authors:  Derk O Verschure; Vivian Bongers; Petronella J Hagen; G Aernout Somsen; Berthe L F van Eck-Smit; Hein J Verberne
Journal:  J Nucl Cardiol       Date:  2014-02-04       Impact factor: 5.952

Review 4.  Standardization of 123I-meta-iodobenzylguanidine myocardial sympathetic activity imaging: phantom calibration and clinical applications.

Authors:  Kenichi Nakajima; Derk O Verschure; Koichi Okuda; Hein J Verberne
Journal:  Clin Transl Imaging       Date:  2017-05-04
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.